TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04221386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melodic Intonation Therapy (MIT)
Description: Subjects will receive at least 6 MIT sessions in group of 3-5 subjects. In the sessions, experimenter will sing songs with the subjects. Songs used in the intervention are familiar to elderly and are rewritten and embedded with everyday phrases and vocabularies. The whole intervention will span 3-4 weeks.
Study: NCT02601651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
Study: NCT05033418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 4-session CBT-I group in addition to IPRP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Pain Rehabilitation Program (IPRP)
Description: 10-week IPRP usual care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary Pain Rehabilitation Program (IPRP)
Description: 10-week IPRP usual care
Study: NCT04508634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Pill
Description: Metformin 1000mg bid
Study: NCT03321487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood-Brain Barrier opening with MRgFUS
Description: ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood-Brain Barrier opening with MRgFUS
Description: ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
Study: NCT00104676

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Description: At least one course administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: At least one course administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: At least one course administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: At least one course administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: At least one course administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: At least one course administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given in a dose-dense sequential fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given in a dose-dense sequential fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given in a dose-dense sequential fashion
Study: NCT00954421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
Study: NCT04508322

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HGA
Description: Headgear Activator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HGA
Description: Headgear Activator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FA
Description: Fixed Orthodontic Appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FA
Description: Fixed Orthodontic Appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FA
Description: Fixed Orthodontic Appliance
Study: NCT04382274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve blocks
Description: the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
Study: NCT01262703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReZolve Stent
Description: ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
Study: NCT03270423

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PathMate2
Description: To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PathMateS
Description: Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
Study: NCT02180022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization, placebo was treated for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onion peel extract
Description: After randomization, onion peel extract was treated for 12 weeks
Study: NCT04046718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture stimulation
Description: stimulation of acupoints of the liver meridian of lv3 lv14
Study: NCT02159560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
Study: NCT02902003

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empowering Families
Description: A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
Study: NCT02762253

Intervention type: DRUG
Group type: OTHER
Intervention: Riboflavin drops
Description: Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
Study: NCT00763867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Study: NCT03565120

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Aggressive Thoracic Radiotherapy
Description: The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)
Study: NCT03252275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer learning
Description: Peer learning plus HBB and ECEB
Study: NCT00617188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
Study: NCT02882087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo plus MTX
Description: All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC18 160 mg plus MTX
Study: NCT00591045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
Study: NCT03819738

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)
Study: NCT02307760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk Fortifier A
Description: Acidified concentrated liquid human milk fortifier

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Milk Fortifier B
Description: Non-acidified concentrated liquid human milk fortifier
Study: NCT04051827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam Oral Solution and Midazolam Intravenous Infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Oral Capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Oral Capsules.
Study: NCT04513704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Description: Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Description: Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Description: Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Description: Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Semaglutide
Description: Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
Study: NCT03331016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart Training
Description: Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Heart to Heart Training
Description: Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
Study: NCT04326127

Intervention type: DEVICE
Intervention: Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)
Description: Data were recorded overnight by both devices simultaneously

Intervention type: DEVICE
Intervention: Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)
Description: Data were recorded overnight by both devices simultaneously
Study: NCT03237182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized TB treatment with multiple drugs
Description: Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized TB treatment with multiple drugs
Description: Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone
Study: NCT04121494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChadOx1 85A - aerosol
Description: Aerosol administration through the Omron MicroAIR NE-U22 nebuliser

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChadOx1 85A - aerosol
Description: Aerosol administration through the Omron MicroAIR NE-U22 nebuliser

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChadOx1 85A - aerosol
Description: Aerosol administration through the Omron MicroAIR NE-U22 nebuliser

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChadOx1 85A - aerosol
Description: Aerosol administration through the Omron MicroAIR NE-U22 nebuliser

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChadOx1 85A - aerosol
Description: Aerosol administration through the Omron MicroAIR NE-U22 nebuliser

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChadOx1 85A - IM
Description: Intramuscular administration
Study: NCT02778256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Description: A specific vestibular stimulation technique is applied to the experimental group

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vestibular stimulation
Description: Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
Study: NCT00690040

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Single balloon catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atad catheter
Description: Double balloon catheter
Study: NCT00825617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Description: Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
Study: NCT00001962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Daclizumab, 1mg/kg, every 2 weeks for a total of 5 infusions.
Study: NCT01882751

Intervention type: DEVICE
Intervention: Conformis CR Total Knee Replacement
Description: iTotal CR by Conformis

Intervention type: DEVICE
Intervention: Off the Shelf
Description: A standard knee replacement not using ConforMIS' iFit technology
Study: NCT04448509

Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral blood mononuclear cell apheresis
Description: Peripheral blood mononuclear cell collection for tumor immunotherapy study of UCAR-T cells
Study: NCT04536987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEXORR
Description: The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
Study: NCT03595683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EDP1503
Description: Taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EDP1503
Description: Taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU).
Study: NCT02133053

Intervention type: OTHER
Intervention: Medical Device, drug-like
Description: Ectoin Allergy Nasal Spray

Intervention type: DRUG
Intervention: Beclomethasone
Description: Beclomethasone nasal spray
Study: NCT02787525

Intervention type: OTHER
Intervention: Questionnaire
Description: A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone.

Intervention type: OTHER
Intervention: Questionnaire
Description: A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone.
Study: NCT00873353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine + erlotinib
Description: 6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days
Study: NCT02725957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose for IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% IV
Study: NCT04058613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALB Protein, Human
Description: Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02673151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) scan
Description: PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).